Anticoagulation in COVID-19: why, what, and when

Abstract

Coronavirus disease-2019, which was declared by the WHO as a global pandemic in March 2020, was seen to be associated with high incidence of thromboembolic complication. The use of prophylactic anticoagulation was seen to have a survival benefit, especially in high-risk patients. The use of higher than standard-dose prophylaxis anticoagulation in critically ill patients may be warranted. There is no recommendation regarding the use of therapeutic dose anticoagulation, except for very high-risk patients only transiently until proving or disproving the presence of thromboembolic complications.

Keywords

• anticoagulation
• covid-19
• heparin
• lmwh